Cannabics Pharmaceuticals Inc (OTCQB: CNBX), a company involved in personalised cannabinoid based cancer medicine, announced yesterday that it has named Itamar Borochov as its new director and member of its board.
Borochov is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies that operate in regulated markets. He was the original founder of Cannabics Pharmaceuticals Inc.
Eyal Barad, CEO and co-founder, said, 'The entire team is pleased to have Itamar return to the board at a very significant time, and I am sure his intimate knowledge and industry experience will significantly contribute to the company as we move into our next planned phases.'
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Cipla partners with Qilu Pharmaceutical for licensing and supply of Keytruda biosimilar in US
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study